The Health100 platform is built upon Google Cloud’s secure, enterprise-ready technology stack to provide a real-time, omni-channel experience. Central to this is the use of agentic AI, which enables ...
Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held biopharmaceutical company. The acquisition focuses on the integration of Enbumyst™ ...
In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while ...
Eton Pharmaceuticals. Eton Pharmaceuticals expands rare disease portfolio through acquisition of U.S. commercialization rights to HEMANGEOL® (propranolol hydrochloride) oral solution. Eton ...
Global life sciences supply chain conference LogiPharma has announced a brand-new series of interactive formats for 2026 under the leadership of incoming event director, Ben Sharples.
In today's Pharma Pulse, the FDA expands the pediatric indication for Juxtapid to treat rare homozygous familial hypercholesterolemia, while Novo Nordisk announces a major €432 million investment in ...
The FDA has transitioned to a "new era" of proactive enforcement, issuing warning letters to telehealth and pharmaceutical companies to eliminate misleading promotional claims and ensure a fair ...
SpotSee and Controlant announced a collaboration to enhance pharmaceutical supply chain visibility using integrated ...
In today’s Pharma Pulse, the FDA grants priority review to a therapy for polycythemia vera, while Novo Nordisk receives expanded pediatric approval for its once-weekly growth hormone.
Thermal testing can make or break cold chain performance. Join this webinar to learn proven best practices that help eliminate blind spots, validate designs, and protect temperature-sensitive ...
The FDA granted accelerated approval to Boehringer Ingelheim’s Hernexeos for first-line HER2-mutant NSCLC following a 44-day ...
In today's Pharma Pulse, the FDA expands the pediatric indication for Juxtapid to treat rare homozygous familial hypercholesterolemia, while Novo Nordisk announces a major €432 million investment in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results